08:42:44 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-16 Kvartalsrapport 2024-Q2
2024-03-28 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-05 Ordinarie utdelning NXTMS 0.00 SEK
2023-03-31 Årsstämma 2023
2023-02-27 Bokslutskommuniké 2022
2022-08-12 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning NXTMS 0.00 SEK
2022-03-31 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-08-13 Kvartalsrapport 2021-Q2
2021-05-17 Split NXTMS 100:1
2021-04-30 Ordinarie utdelning NXTMS 0.00 SEK
2021-04-29 Årsstämma 2021
2021-03-01 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-14 Kvartalsrapport 2020-Q2
2020-04-01 Ordinarie utdelning NXTMS 0.00 SEK
2020-02-28 Bokslutskommuniké 2019
2019-11-11 Extra Bolagsstämma 2019
2019-08-16 Kvartalsrapport 2019-Q2
2019-03-26 Ordinarie utdelning NXTMS 0.00 SEK
2019-03-25 Årsstämma 2019
2019-03-04 Bokslutskommuniké 2018
2018-11-26 Split NXTMS 30:1
2018-11-21 Extra Bolagsstämma 2018
2018-08-16 Kvartalsrapport 2018-Q2
2018-03-29 Ordinarie utdelning NXTMS 0.00 SEK
2018-03-28 Årsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-03-29 Ordinarie utdelning NXTMS 0.00 SEK
2017-03-28 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2017-02-17 Extra Bolagsstämma 2017
2016-08-17 Kvartalsrapport 2016-Q2
2016-04-01 Ordinarie utdelning NXTMS 0.00 SEK
2016-03-31 Årsstämma 2016
2016-02-29 Bokslutskommuniké 2015
2015-12-22 Extra Bolagsstämma 2015
2015-08-20 Kvartalsrapport 2015-Q2
2015-04-01 Ordinarie utdelning NXTMS 0.00 SEK
2015-03-31 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014

Beskrivning

LandFinland
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Nexstim är verksamt inom medicinteknik. Bolaget har utvecklat en icke-invasiv teknik för hjärnstimulering som kallas SmartFocus®. Det är en navigerad magnetisk stimuleringsteknik (nTMS) med 3D-navigering som ger inriktning av TMS till det specifika området av hjärnan. Tekniken är avsedd för behandling av svår depression och kronisk neuropatisk smärta. Bolaget grundades år 2000 och har sitt huvudkontor i Helsingfors.
2022-10-25 08:00:00

Press release, Helsinki, 25 October 2022 at 9 AM (EEST)

Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received an NBT® system order from Alamo Neurosurgical Institute (ANI) in San Antonio, Texas.

Nexstim NBT® systems uses the unique SmartFocus® TMS technology that enables accurate stimulation of the targeted area in the brain. NBT® system is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.  

Mikko Karvinen, CEO of Nexstim, says: We are very happy to announce the sale of this system to Alamo Neurosurgical. The therapy business continues to be a key part of our growth strategy as our competitive advantages are numerous in this field. We are glad to see an increasing number of patients benefiting from our SmartFocus® TMS technology.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com